Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report ; volume:3 ; number:1 ; day:27 ; month:8 ; year:2009 ; pages:1-3 ; date:12.2009
Journal of medical case reports ; 3, Heft 1 (27.8.2009), 1-3, 12.2009
- Urheber
-
Gatzonis, Stylianos
- Beteiligte Personen und Organisationen
-
Siatouni, Anna
SpringerLink (Online service)
- DOI
-
10.4076/1752-1947-3-8955
- URN
-
urn:nbn:de:1111-201607109783
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gatzonis, Stylianos
- Siatouni, Anna
- SpringerLink (Online service)
Ähnliche Objekte (12)
Relapsing/remitting type 1 diabetes
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Relapsing/remitting type 1 diabetes
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Relapsing/remitting type 1 diabetes
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab